New Breast Cancer Treatment
FDA Approves AstraZeneca Camizestrant to Cut Breast Cancer Progression Risk
Anonymous
Key Points
1
A subsequent pre-planned SERENA-6 analysis found that the camizestrant combination also improved progression-free survival after the next line of treatment: median PFS2 was 25.7 months versus 19.1 months with standard therapy, with a hazard ratio of 0.63. Overall-survival follow-up is continuing, with an interim hazard ratio of 0.87.
2
In SERENA-6, the safety profile of camizestrant combined with palbociclib, ribociclib or abemaciclib was consistent with the known profiles of the individual medicines; no new safety concerns were identified, and treatment discontinuations were very low and similar between the study arms.
3
The pivotal SERENA-6 results were presented at the 2025 American Society of Clinical Oncology annual meeting and published simultaneously in The New England Journal of Medicine.
4
Trial investigator Kevin Kalinsky said the approach allows clinicians to intervene before clinical or radiographic progression, rather than waiting until the cancer becomes harder to treat and patients’ outcomes and quality of life worsen.
5
AstraZeneca described the decision as the FDA’s 10th approval across its portfolio that year and its fourth approval in breast cancer, according to oncology executive Dave Fredrickson.
AstraZeneca's Etcamah (camizestrant) has won FDA accelerated approval to treat a specific type of advanced breast cancer that develops resistance mutations during standard therapy OncoDaily. The drug, given with a CDK4/6 inhibitor, cut the risk of disease progression or death by 56% in clinical trials and extended median progression-free survival to 16 months from 9.2 months MarketScreener. The approval includes a companion diagnostic test that detects ESR1 resistance mutations in blood, allowing doctors to switch treatment before cancer visibly worsens on imaging.
This strategy targets roughly one-third of patients with HR-positive, HER2-negative breast cancer whose tumors develop ESR1 mutations during aromatase inhibitor and CDK4/6 therapy MarketScreener. It marks a shift toward catching cancer resistance earlier, using liquid biopsy blood tests rather than waiting for visible disease progression on CT scans or X-rays.
SERENA-6 Trial Showed Dual Survival Gains
The approval rests on the SERENA-6 trial, which compared camizestrant plus a CDK4/6 inhibitor against standard therapy in patients with ESR1-mutated tumors OncoDaily. The combo improved not just first-line progression-free survival but also second-line survival: median PFS2 reached 25.7 months versus 19.1 months, a 36% risk reduction OncoDaily. Interim overall-survival data showed a hazard ratio of 0.87, though longer follow-up continues.
Trial investigator Kevin Kalinsky emphasized the clinical advantage: doctors can now intervene before cancer becomes visible on imaging, preventing patients' outcomes and quality of life from deteriorating OncoDaily. This early intervention approach represents a fundamental shift in how resistant breast cancers are managed.
Blood Test Companion Diagnostic Enables Early Detection
The FDA also approved Guardant360 CDx as a companion diagnostic to detect ESR1 mutations in circulating tumor DNA from blood samples NASDAQ. This liquid biopsy test allows oncologists to identify resistance mutations before the cancer progresses on CT or MRI scans NASDAQ. Early detection enables timely treatment switches, potentially preventing more aggressive disease from developing.
The combination of camizestrant plus circulating-tumor-DNA monitoring represents precision medicine in action MarketScreener. Instead of guessing when to change therapy, doctors now have a molecular signal telling them exactly when resistance has emerged.
Safety Profile Mirrors Individual Drug Profiles
In SERENA-6, camizestrant combined with palbociclib, ribociclib, or abemaciclib showed a safety profile consistent with each drug's known effects OncoDaily. No new safety concerns emerged. Treatment discontinuations were very low and similar between the study arms, indicating patients tolerated the combination well OncoDaily.
AstraZeneca oncology executive Dave Fredrickson called the approval the company's fourth breast cancer approval that year and its 10th approval overall across its portfolio OncoDaily. The SERENA-6 results were published simultaneously in The New England Journal of Medicine and presented at the 2025 American Society of Clinical Oncology annual meeting.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
58
Reach
75
A
AnonymousAuthor
